A phase II trial of GTP-004 in Myasthenia Gravis patients

Trial Profile

A phase II trial of GTP-004 in Myasthenia Gravis patients

Planning
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Ondansetron/pyridostigmine (Primary)
  • Indications Myasthenia gravis
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Mar 2018 According to a GT Biopharma media release, based on additional data from phase 1 study the company expects to potentially accelerate the start of its Phase 2 trial in MG patients to the third quarter of 2018.
    • 29 Jan 2018 New trial record
    • 24 Jan 2018 According to a GT Biopharma media release, this trial is expected to begin in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top